GlassScriptPhysician profile
Amy Delane Adams
NPI 1396993663
$10,594.09
in general payments reported to CMS, 2019-2025
36 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 86% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,375 · 2020: $1,122 · 2021: $1,081 · 2022: $1,734 · 2023: $1,615 · 2024: $1,922 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,831 · Education: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,831.32 |
| Education | $450.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,634.53 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,789.80 | 2019-2025 | |
| Janssen Biotech, INC. | $689.35 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Genzyme Corporation | $585.28 | 2019-2025 | |
| Amgen INC. | $551.22 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $464.55 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $455.31 | 2019-2025 | Blu-U |
| Incyte Corporation | $399.12 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $388.03 | 2021-2025 | Nemluvio |
| Lilly USA, LLC | $365.16 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Leo Pharma INC. | $308.45 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| E.R. Squibb & Sons, L.L.C. | $278.60 | 2022-2025 | Sotyktu |
| Pfizer INC. | $266.03 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $157.57 | 2019-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $153.41 | 2023-2025 | Zoryve |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $123.52 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.99 | 2022-2025 | Spevigo |
| Almirall LLC | $118.44 | 2020-2025 | Klisyri, Seysara |
| Mallinckrodt Hospital Products INC. | $100.64 | 2025 | Acthar |
| Stemline Therapeutics INC. | $95.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Organon LLC | $47.00 | 2025 | Vtama |
| Hill Dermaceuticals, INC. | $46.65 | 2023-2024 | Tolak |
| Medimetriks Pharmaceuticals, INC. | $45.19 | 2019 | |
| Mayne Pharma Commercial LLC | $43.28 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $41.61 | 2020-2021 | |
| Dermavant Sciences, INC. | $40.95 | 2023-2024 | Vtama |
| Merck Sharp & Dohme LLC | $38.21 | 2022-2023 | Keytruda |
| Kyowa Kirin, INC. | $27.87 | 2019 | |
| Botanix Sb INC | $25.89 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $22.35 | 2019-2021 | |
| Biofrontera INC. | $19.58 | 2019 | |
| Dusa Pharmaceuticals, INC. | $15.99 | 2019 | |
| Bioventus LLC | $15.32 | 2023 | |
| Misonix INC | $14.37 | 2021 | |
| Sandoz INC. | $13.81 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.